Literature DB >> 24503463

Glassy cell carcinoma of the cervix: a systematic review and meta-analysis.

Camilla Guitarte1, Ioannis Alagkiozidis2, Benjamin Mize1, Erin Stevens1, Ghadir Salame1, Yi-Chun Lee1.   

Abstract

OBJECTIVE: The purpose of this study is to summarize the data on the incidence, clinical behavior and overall survival of patients with glassy cell cervical carcinoma (GCCC).
METHODS: Twenty-four case series and fifteen case reports identified by searching PubMed database qualified for inclusion in this study. The published cases were combined with data from a retrospective chart review of patients with GCCC in two major teaching hospitals in Brooklyn, NY.
RESULTS: A total of 292 cases were collected through our literature and chart review. Median age at diagnosis was 45 years old (range 12-87 years of age). GCCC incidence ranges from 0.2 to 9.3% of all cervical cancers and 2 to 30.2% of cervical adenocarcinomas. The stage distribution is similar to squamous cell carcinoma with 79% of the patients being diagnosed with Stage I or II disease. Most common sites of recurrence for Stage I patients are the vagina and pelvis. In Stage II patients locoregional and distant metastases are equally common. Recurrence rate was higher among patients treated only with surgery (32.7%), as compared to patients treated with surgery followed by radiation (11%) or patients treated with radiation only (10%). Median overall survival (OS) was 25 months (95% CI 8.4-41.6). Overall 5-year survival for all stages is lower when compared to all cervical cancers (54.8% vs 75%). There was no interaction between race and OS (p=0.66).
CONCLUSION: GCCC is a rare histologic type of cervical cancer that presents at a younger age, is associated with high risk for distant failure and carries worse prognosis as compared to the squamous cell type. Radiation therapy is associated with decreased risk of recurrence.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cervix; Glassy cell carcinoma; Metaanalysis

Mesh:

Substances:

Year:  2014        PMID: 24503463     DOI: 10.1016/j.ygyno.2014.01.048

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  9 in total

1.  Immunohistochemical analysis of glassy cell carcinoma of the cervix reveals robust lymphocyte infiltrate and the expression of targetable inhibitory immune checkpoints.

Authors:  Erin A Blake; Malcolm S Ross; Megan E Ross; Koji Matsuo; Emily T Silverstein; Lilibeth R Torno; Rohit Bhargava; Miriam D Post; Diane M Da Silva; Sarah Taylor; Saloni Walia; Lynda Roman; Troy A McEachron
Journal:  Arch Gynecol Obstet       Date:  2021-08-15       Impact factor: 2.344

2.  Effectiveness and prognostic factors of apatinib treatment in patients with recurrent or advanced cervical carcinoma: A retrospective study.

Authors:  Hui Yang; Min Chen; Zijie Mei; Conghua Xie; Yunfeng Zhou; Hui Qiu
Journal:  Cancer Med       Date:  2021-05-13       Impact factor: 4.452

3.  Clinical outcomes of advanced-stage glassy cell carcinoma of the uterine cervix: a need for reappraisal.

Authors:  Nara Yoon; Ji-Ye Kim; Hyun-Soo Kim
Journal:  Oncotarget       Date:  2016-11-29

4.  HPV-negative Tumors in a Swedish Cohort of Cervical Cancer.

Authors:  Malin Kaliff; Mats G Karlsson; Bengt Sorbe; Louise Bohr Mordhorst; Gisela Helenius; Gabriella Lillsunde-Larsson
Journal:  Int J Gynecol Pathol       Date:  2020-05       Impact factor: 2.762

5.  A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy.

Authors:  Hui Yang; Shaoxing Sun; Zijie Mei; Qingming Xiang; Chunxu Yang; Min Chen; Conghua Xie; Yunfeng Zhou; Hui Qiu
Journal:  Drug Des Devel Ther       Date:  2021-11-16       Impact factor: 4.162

6.  A Unique Glassy Cell Carcinoma (GCC) of the Cervix Diagnosed during Pregnancy-A Case Report.

Authors:  Marlena Grabowska; Ewa Baum; Małgorzata Lewandowska; Stefan Sajdak; Klaudia Dolińska-Kaczmarek; Monika Englert-Golon
Journal:  Healthcare (Basel)       Date:  2022-08-21

7.  Immune and inflammation: related factor alterations as biomarkers for predicting prognosis and responsiveness to PD-1 monoclonal antibodies in cervical cancer.

Authors:  Xihan Liu; Xi Zhang; Chang Liu; Wendi Mu; Jin Peng; Kun Song
Journal:  Discov Oncol       Date:  2022-09-28

8.  Glassy cell carcinoma of cervix: an analysis for 20 cases and literatures review.

Authors:  Qingxuan Wang; Yuanjing Hu; Ya He; Tian Wang; Pratima Ghimire
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

9.  Adenosquamous Carcinoma of the Uterine Cervix - Impact of Histology on Clinical Management.

Authors:  Angel Yordanov; Stoyan Kostov; Stanislav Slavchev; Strahil Strashilov; Assia Konsoulova; Jean Calleja-Agius; Riccardo Di Fiore; Sherif Suleiman; Paul Kubelac; Catalin Vlad; Patriciu Achimas-Cadariu; Mariela Vasileva-Slaveva
Journal:  Cancer Manag Res       Date:  2021-06-23       Impact factor: 3.989

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.